Novel approaches in cancer immunotherapy - A light at the end of the tunnel

Monika Joshi, Sumanta K. Pal, Joseph Drabick

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

After decades of disappointments, the use of immunotherapy in cancer has finally come of age and resulted in a real paradigm shift in cancer treatment across many tumor types. With the advent of novel immunotherapies based on increasing understanding of the human immune system, cure has become a real possibility for many patients. The development of cancer vaccines, immune checkpoint inhibitors, chimeric antigen receptor T cell, oncolytic virus based immunotherapy to name a few have given hope to patients. One of the most exciting developments in the era of immunotherapy has been the discovery of checkpoint inhibitors causing blockade of two important immune pathways -- cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor-1 (PD-1), resulting in empowerment of anti-tumor immunity. However, only a select group of patients respond to these immunotherapies, highlighting a need for novel strategies that could help transform the non-responders to responders' category. This article highlights various immunotherapeutic agents and strategies using them and other modalities in the treatment of solid tumors.

Original languageEnglish (US)
JournalDiscovery medicine
Volume21
Issue number118
StatePublished - Jan 1 2016

Fingerprint

Immunotherapy
Neoplasms
Hope
Oncolytic Viruses
TNF-Related Apoptosis-Inducing Ligand Receptors
Cancer Vaccines
Cytotoxic T-Lymphocytes
T-Cell Antigen Receptor
Names
Immune System
Immunity
Therapeutics
Proteins

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{14472b335dcd4905952b1f3a30abd768,
title = "Novel approaches in cancer immunotherapy - A light at the end of the tunnel",
abstract = "After decades of disappointments, the use of immunotherapy in cancer has finally come of age and resulted in a real paradigm shift in cancer treatment across many tumor types. With the advent of novel immunotherapies based on increasing understanding of the human immune system, cure has become a real possibility for many patients. The development of cancer vaccines, immune checkpoint inhibitors, chimeric antigen receptor T cell, oncolytic virus based immunotherapy to name a few have given hope to patients. One of the most exciting developments in the era of immunotherapy has been the discovery of checkpoint inhibitors causing blockade of two important immune pathways -- cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor-1 (PD-1), resulting in empowerment of anti-tumor immunity. However, only a select group of patients respond to these immunotherapies, highlighting a need for novel strategies that could help transform the non-responders to responders' category. This article highlights various immunotherapeutic agents and strategies using them and other modalities in the treatment of solid tumors.",
author = "Monika Joshi and Pal, {Sumanta K.} and Joseph Drabick",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "21",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "118",

}

Novel approaches in cancer immunotherapy - A light at the end of the tunnel. / Joshi, Monika; Pal, Sumanta K.; Drabick, Joseph.

In: Discovery medicine, Vol. 21, No. 118, 01.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel approaches in cancer immunotherapy - A light at the end of the tunnel

AU - Joshi, Monika

AU - Pal, Sumanta K.

AU - Drabick, Joseph

PY - 2016/1/1

Y1 - 2016/1/1

N2 - After decades of disappointments, the use of immunotherapy in cancer has finally come of age and resulted in a real paradigm shift in cancer treatment across many tumor types. With the advent of novel immunotherapies based on increasing understanding of the human immune system, cure has become a real possibility for many patients. The development of cancer vaccines, immune checkpoint inhibitors, chimeric antigen receptor T cell, oncolytic virus based immunotherapy to name a few have given hope to patients. One of the most exciting developments in the era of immunotherapy has been the discovery of checkpoint inhibitors causing blockade of two important immune pathways -- cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor-1 (PD-1), resulting in empowerment of anti-tumor immunity. However, only a select group of patients respond to these immunotherapies, highlighting a need for novel strategies that could help transform the non-responders to responders' category. This article highlights various immunotherapeutic agents and strategies using them and other modalities in the treatment of solid tumors.

AB - After decades of disappointments, the use of immunotherapy in cancer has finally come of age and resulted in a real paradigm shift in cancer treatment across many tumor types. With the advent of novel immunotherapies based on increasing understanding of the human immune system, cure has become a real possibility for many patients. The development of cancer vaccines, immune checkpoint inhibitors, chimeric antigen receptor T cell, oncolytic virus based immunotherapy to name a few have given hope to patients. One of the most exciting developments in the era of immunotherapy has been the discovery of checkpoint inhibitors causing blockade of two important immune pathways -- cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor-1 (PD-1), resulting in empowerment of anti-tumor immunity. However, only a select group of patients respond to these immunotherapies, highlighting a need for novel strategies that could help transform the non-responders to responders' category. This article highlights various immunotherapeutic agents and strategies using them and other modalities in the treatment of solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=85007361394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007361394&partnerID=8YFLogxK

M3 - Article

C2 - 27448784

AN - SCOPUS:85007361394

VL - 21

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 118

ER -